Гемифлоксацин в лечении внебольничных инфекций нижних дыхательных путей у взрослых


А.И. Синопальников

Гемифлоксацин – один из новых представителей класса фторхинолонов, относящийся к IV поколению. Среди фторхинолонов гемифлоксацин характеризуется самой высокой антипневмококковой активностью и не уступает при этом “классическому” фторхинолону – ципрофлоксацину – по действию на грамотрицательную флору, а “респираторным” фторхинолонам – по активности в отношении внутриклеточных возбудителей. Гемифлоксацин характеризуется благоприятными фармакокинетическими параметрами и низким потенциалом к формированию резистентности микроорганизмов. В рандомизированных клинических исследованиях показана высокая клиническая и бактериологическая эффективность, а также хороший профиль переносимости препарата при лечении пациентов с внебольничной пневмонией и обострением хронического бронхита/хронической обструктивной болезни легких.

Литература






  1. Emmerson AM, Jones AM. The quinolones: decades of development and use. JАC 2003;51(Suppl. S1):13–20.

  2. Anderson MI, MacGowan AP. Development of the quinolones. JАС 2003;51(Suppl. S1):1–11.

  3. Paul Ehrlich Society for Chemotherapy and the German Respiratory Association. Rational treatment of bacterial respiratory tract infections. Chemother J 2000;9:3–23.

  4. Chang Yong Hong. Discovery of gemifloxacin (Factive, LB2o304a): a quinolone of a new generation. Il Farmaco 2001;56:41–44.

  5. Hoban DJ, Bouchillon SK, Johnson JL, et al. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study. Diagn Microb Infect Dis 2001;40:51–57.

  6. Koeth LM, Jacobs MR, Bajaksouzian S, et al. Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in Unated States in 1999–2000. Intern J Antimicrob Agents 2002;19:33–37.

  7. Blondeau JM, Missaghi B. Gemifloxacin: a new fluoroquinolone. Expert Opin Pharmacother 2004;5:1117–52.

  8. Davis SL, Neuhauser MM, McKinnon. Quinolones // www.antimicrobe.org/

  9. Zanel GG, Noreddin AM. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr Opin Pharmacol 2001;1:459–63.

  10. Allen A, Bygate E, Clark D, et al. The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers. Intern J Antimicrob Agents 2000;16:45–50.

  11. Allen A, Bygate E, Faessel H, et al. The effect of ferrous sulphate and sucralfate on the bioavailability of oral gemifloxacin in healthy volunteers. Intern J Antimicrob Agents 2000;15:283–89.

  12. Hooper DC. Mechanisms of fluoroquinolone resistance. Drug Resistance Updates 1999;2:38–55.

  13. Mandell L (personal communication).

  14. File TM, Schlemmer B, Garau J, et al. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparisoin with trovafloxacin. JAC 2001;48:67–74.

  15. Lode H, File TM, Mandell L, et al. Oral gemifloxacin versus sequental therapy with intravenosus ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumoniae: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Therapeut 2002;24:1915–36.

  16. Leophonte P, File TM, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med 2004;98:708–20.

  17. Wilson R, Schentage JJ, Ball P, et al. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Therapeut 2002;24:639–52.

  18. Wilson R, Langan C, Ball P, et al. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respir Med 2003;97:242–49.

  19. Stahlmann R. Clinical toxicological aspects of fluoroquinolones. Toxicology Letters 2002;127: 269–77.

  20. Chen H, Bloch K, Maclean J. Acute eosinophilic hepatitis from trovafloxacin. N Engl J Med 2000;342:359–60.

  21. Data on file. Oscient Pharmaceuticals.

  22. Ball P, Mandell L, Patou G, et al. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int J Antimicrob Agents 2004;23: 421–29.



Бионика Медиа